The use of GLP-1 and GIP receptor agonists has seen a global increase, with various medications falling into this class, including injectable options like Semaglutide (Ozempic®, Wegovy®), Tirzepatide (Mounjaro®, Zepbound™), and an orally delivered drug (Rybelsus®). The high demand for these medications has led to their inclusion on the FDA’s Drug Shortage List. Consequently, the FDA has issued guidance for compounding pharmacies to address the shortage by producing essential alternatives to these patented drugs, as long as they remain on the FDA’s Shortage List.
VH Pharmacy can compound both Semaglutide and Tirzepatide in a sublingual form. We understand that individuals may wish to avoid injections due to various changes and storing these medications. Sublingual options may also help to reduce unwanted side effects, such as severe nausea and headaches. Our sublingual suspension is dispensed in a bottle with an oral syringe for precise dosing.
GLP-1 and GIP receptor agonists function by increasing insulin release from the pancreas in response to food, reducing sugar release from the liver into the bloodstream, and slowing down the emptying of the stomach after meals. This helps regulate blood glucose levels and induces a sense of fullness, leading to gradual weight loss. These medications are intended to complement diet and exercise in improving blood glucose levels in adults with type 2 diabetes mellitus and are not suitable for patients with type 1 diabetes.
If you are interested in more information or getting started, please contact VH Pharmacy. Our team can speak to your healthcare provider or refer one to you. Let us know how we can help you!
